The goal of this clinical trial to learn what dose/s of caffeine citrate works to treat preterm born babies who have episodes where they stop breathing. It will also learn about the safety of different doses of caffeine citrate for the variety of preterm-born babies that are prescribed this.
The main question it aims to answer is: Which dose is the optimal dose of caffeine citrate for very preterm babies to prevent short-term death and disease?
Researchers will compare three different doses of caffeine citrate, which are already used in clinical practice to treat breathing stoppages in preterm babies, to see which dose works best. No placebo will be used.
Participants will be given a 'loading' dose of caffeine citrate <72 hours of life, and a smaller 'maintenance' dose once a day, for as long as the baby needs this.
This trial will be undertaken as part of the PLATIPUS trial (NCT06461429).

开始日期2025-10-01

申办/合作机构

University of Melbourne

NCT06972108

/ Not yet recruiting临床2期IIT

Caffeine for Oxygen Dependent Meconium Aspiration Syndrome

When babies are stressed in the womb, they sometimes pass meconium in the amniotic fluid. When this happens, they may swallow the meconium-stained fluid into their lungs which may cause them to have poor oxygen levels and require resuscitation and significant breathing support in the early hours after birth. This is referred to as Meconium Aspiration Syndrome (MAS). Some babies may recover slowly and require breathing and/or oxygen support for days. Caffeine is a drug that can help improve breathing efforts and is commonly used in premature babies who do not have regular or strong breathing efforts. Caffeine has been used in babies with MAS who recovered slowly (i.e. requiring breathing or oxygen support for a longer period) for several years now. Despite having success in many babies, there is no evidence to examine its effectiveness and mechanism of action. This pilot study proposes to look at the effects of caffeine in babies with MAS who require ongoing breathing and oxygen support. There will also be examination of whether caffeine improves breathing efforts with better lung opening using ultrasound images of the lungs.

开始日期2025-09-01

申办/合作机构

University of Alberta

NCT06638372

/ Not yet recruitingN/AIIT

Caffeinated Chewing Gum on Special Forces Performance: a Cross-over Study

The purpose of this project is to investigate the effects of caffeine chewing gum on the cognitive functions and special operations capabilities of special forces.

开始日期2025-07-01

申办/合作机构-

100 项与枸橼酸咖啡因相关的临床结果

登录后查看更多信息

100 项与枸橼酸咖啡因相关的转化医学

登录后查看更多信息

100 项与枸橼酸咖啡因相关的专利（医药）

登录后查看更多信息

44,364

项与枸橼酸咖啡因相关的文献（医药）

2025-12-31·Journal of the International Society of Sports Nutrition

Caffeine supplementation improved movement patterns and reactive agility in rugby sevens matches in male collegiate players

Article

作者: Hsueh, Chang-Li ; Sun, Cheng-Yen ; Chang, Chen-Kang

PURPOSE:

Rugby sevens is a high-intensity contact sport often played in two-day tournaments. Caffeine is widely used by rugby players for its performance-enhancing effects. This study aimed to investigate the impact of caffeine supplementation on various performance metrics, including distance covered at different speeds, acceleration, deceleration, collisions, and repeated high-intensity efforts across four matches over two consecutive days in collegiate male rugby sevens players. Reactive agility, a key performance attribute in rugby sevens, was also assessed before each match.

METHODS:

A position-matched, double-blind, randomized crossover design was employed, with six male collegiate rugby players (mean height: 1.78 ± 0.09 m, mean weight: 81.3 ± 9.2 kg, mean age: 21.5 ± 0.8 years) participating in two trials. Each trial consisted of a two-day tournament, with two matches per day. Performance was monitored using global positioning system units to track distance covered in various speed zones, as well as total distance, frequency of acceleration, deceleration, collisions, and repeated high-intensity efforts.

RESULTS:

The results indicated that in the placebo trial, participants covered significantly more distance at a walking pace (0-6 km/h) in match 4 compared to match 3 (match 3: 480.3 ± 32.7 m; match 4: 629.4 ± 21.3 m, p < 0.001, d = 0.117). In the caffeine trial, players covered significantly more distance at a jogging pace (6-12 km/h) in match 4 compared to the placebo trial (caffeine: 405.9 ± 9.8 m; placebo: 303.6 ± 20.2 m, p = 0.015, d = 1.693). Reactive agility was significantly better in the caffeine trial before match 3 (caffeine trial: 1.80 ± 0.17 s; placebo trial: 2.07 ± 0.18 s, p = 0.038, d = 0.858).

CONCLUSIONS:

Caffeine supplementation at 3 mg/kg may increase jogging and reduce walking and standing in the final match of a two-day rugby sevens tournament, while also improving reactive agility on the second day. This suggests that by mitigating fatigue in the later stages of the tournament, caffeine allowed players to shift from low-intensity activities to higher-intensity efforts. These adjustments may improve both offensive and defensive performance during rugby sevens matches. Therefore, rugby sevens players could benefit from taking caffeine supplements in the later stages of 2-day tournaments to optimize their performance.

2025-12-31·Journal of the International Society of Sports Nutrition

Effects of different dietary supplements on athletic performance in soccer players: a systematic review and network meta-analysis

Review

作者: Zhu, Xiaolin ; Nasharuddin, Nurul Amelina ; Xiang, Changqing ; Tengku Kamalden, Tengku Fadilah ; Luo, Hua

BACKGROUND:

As dietary supplements play a crucial role in meeting the unique nutritional needs of soccer players, a growing body of studies are exploring the effects of dietary supplements on athletic performance in soccer players. The effectiveness of certain supplements, such as caffeine and creatine, remains debated due to inconsistent results across studies. Therefore, this systematic review and Bayesian network meta-analysis was conducted to tentatively identify the most effective dietary supplements for soccer players.

METHODS:

We searched PubMed, Web of Science, Cochrane, Embase, and SPORTDiscus from database establishment to 5 February 2024 to identify randomized controlled trials (RCTs) evaluating the effects of different dietary supplements on athletic performance in soccer players. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials. A Bayesian network meta-analysis was performed using the R software and Stata 18.0. A subgroup analysis was conducted based on the competitive level of the athletes.

RESULTS:

Eighty RCTs were included, with 1,425 soccer players randomly receiving 31 different dietary supplements or placebo. The network meta-analysis showed that compared with placebo, carbohydrate + protein (SMD: 2.2, very large), carbohydrate + electrolyte (SMD: 1.3, large), bovine colostrum (SMD: moderate) and caffeine (SMD: 0.29, small) were associated with a significant effect on increasing the distance covered. Kaempferia parviflora (SMD: 0.46, small) was associated with a significant effect on enhancing muscular strength. Beta-alanine (SMD: 0.83, moderate), melatonin (SMD: 0.75, moderate), caffeine (SMD: 0.37, small), and creatine (SMD: 0.33, small) were associated with a significant effect on enhancing jump height. Magnesium creatine chelate (SMD: -3.0, very large), melatonin (SMD: -1.9, large), creatine + sodium bicarbonate (SMD: -1.4, large), and arginine (SMD: -1.2, moderate) were associated with a significant effect on decreasing sprint time. Creatine + sodium bicarbonate (SMD: -2.3, very large) and caffeine (SMD: -0.38, small) were associated with a significant effect on improving agility. Sodium pyruvate (SMD: 0.50, small) was associated with a significant effect on increasing peak power. Magnesium creatine chelate (SMD: 1.3, large) and sodium pyruvate (SMD: 0.56, small) were associated with a significant effect on increasing mean power. Carbohydrate + electrolyte (SMD: -0.56, small) was associated with a significant effect on improving the rating of perceived exertion.

CONCLUSIONS:

This study suggests that a range of dietary supplements, including caffeine, creatine, creatine + sodium bicarbonate, magnesium creatine chelate, carbohydrate + electrolyte, carbohydrate + protein, arginine, beta-alanine, bovine colostrum, Kaempferia parviflora, melatonin, and sodium pyruvate, can improve athletic performance in soccer players. This review provides evidence-based guidance for soccer coaches and nutritionists on using dietary supplements to enhance specific performance measures.

2025-12-31·Journal of the International Society of Sports Nutrition

Acute effects of isolated and combined dietary nitrate and caffeine ingestion on ergometer-based 1000 m time trial performance in highly trained kayakers

Article

作者: Bruhn, Sven ; Weippert, Matthias ; Mittlmeier, Thomas ; Behrens, Martin ; Pollex, Johannes

BACKGROUND:

Dietary nitrate (BR) and caffeine (CAF) ingestion have been shown to increase sports performance. However, the isolated and combined effects of BR and CAF ingestion on time trial (TT) performance as well as the accompanying physiological and perceptual responses have never been investigated in highly trained kayak athletes. Therefore, the present study examined the impact of an isolated and combined supplementation with BR (140 ml beetroot concentrate, ~12.5 mmol nitrate) and CAF (3 mg/kg bodyweight) on 1000 m ergometer TT performance as well as the accompanying physiological (i.e. cardiorespiratory function, muscle oxygenation, muscle activity) and perceptual responses (i.e. fatigue, effort, and exercise-induced pain perception) in male highly trained kayakers. It was hypothesized that the isolated ingestion of BR and CAF would both improve ergometer-based 1000 m TT performance and induce supplement-specific physiological and perceptual responses. Considering the primary effects of BR on muscle function and of CAF on the central nervous system, it was further assumed that the combined ingestion will result in an additional performance increase and supplement-specific physiological and perceptual responses.

METHODS:

Using a prospective, randomized, controlled, double-blind crossover design, 12 male highly trained kayak athletes from local clubs were investigated. They completed four measurement sessions resulting in four randomized conditions: (i) BR+CAF; (ii) BR+CAF placebo (BR+PLA); (iii) CAF+BR placebo (CAF+PLA); and (iv) BR placebo + CAF placebo (PLA+PLA). An air-braked instrumented kayak-ergometer was used to record 1000 m TT performance, power output, and stroke frequency. Heart rate (HR), oxygen uptake (VO₂), maximum VO₂ (VO_2max), respiratory equivalent of O₂ (VE/VO₂), and carbon dioxide (VE/VCO₂) were measured continuously. Furthermore, oxygenation of the deltoid muscle was measured with near-infrared spectroscopy (mNIRS) and muscle activity of nine unilateral muscles with surface electromyography (i.e. deltoideus, serratus anterior, triceps brachii caput lateralis, trapezius, infraspinatus, latissimus dorsi, obliquus externus, flexor carpi radialis, and vastus lateralis muscle) during the 1000 m TT. After the TT, fatigue, effort, and exercise-induced pain perception were queried. One- and two-way analysis of variance with repeated measures were conducted to determine differences between conditions for the entire 1000 m TT and predefined sections (0-50 m, 50-100 m, 100-150 m, 150-250 m, 250-500 m, 500-750 m, 750-1000 m), respectively (p ≤ 0.05).

RESULTS:

The supplements did not have an ergogenic effect on TT performance compared to the PLA+PLA condition, either in isolation or in combination. The same applied to the majority of physiological parameters and the perceptual responses. Nevertheless, VE/VO₂ was lower during the sections 150-250 m (-5.00%; p = 0.02) and 250-500 m (-3.49%; p = 0.03) in the BR+PLA condition, whereby VE/VCO₂ was higher during the section 150-250 m (4.19%; p = 0.04) in the CAF+PLA compared to the PLA+PLA condition, respectively.

CONCLUSIONS:

Data indicate that the isolated and combined ingestion of BR and CAF had no effect on 1000 m TT performance, the majority of physiological responses, and perceptual responses in highly trained kayakers. These findings might be related to the dosage and/or a ceiling effect due to the already efficient vascular, metabolic, and muscle function, including high amounts of endogenous produced nitric oxide, in athletes.

181

项与枸橼酸咖啡因相关的新闻（医药）

2025-05-02

·梅斯医学

对于不少打工人来说，一天的精气神都藏在早上的那杯咖啡里。不来一口，浑身不得劲，脑子都运转不起来。更别说各种研究也“撑腰”了：适量喝咖啡能降低心血管疾病风险、延缓记忆力衰退、甚至还能缓解抑郁情绪。这不，咖啡几乎成了现代人“续命水”的代名词。但就在大家安心“续命”的时候，来自哈尔滨医科大学附属肿瘤医院的研究团队发表于European Journal of Nutrition的一项重磅研究[1]，突然泼来一盆冷水——长期血浆咖啡因水平较高，与肺癌风险增加54％显著相关！基因为咖啡因“暗渡陈仓”为了探究血浆咖啡因水平是否与癌症风险存在因果关系，研究团队采用了MR方法。这个方法能借助基因在出生时的“随机分布”特性，来帮助我们判断某个风险因素（比如咖啡因）到底是“巧合”关联，还是“真有因果”。事实上，咖啡因在人体内的代谢主要靠CYP1A2酶完成，而这个酶的活性又受一个上游基因——AHR（芳香烃受体）的调控。研究团队筛选出8个与血浆咖啡因水平密切相关的SNP（基因位点），以此作为“工具变量”，正式开展MR分析。那么。咖啡因究竟为何“翻车”？对此，研究者也提出了其中潜在的机制：其一，抗氧化能力的下降被认为是促进肺部细胞发生癌变的关键路径之一。一旦咖啡因削弱了抗氧化系统，细胞更容易受到氧化应激和DNA损伤，从而可能提高癌症风险。另外，咖啡因还有一个“隐蔽身份”——ATM激酶的抑制剂。ATM激酶是细胞应对DNA损伤的重要信号分子之一。一旦DNA受损，ATM就会启动p53通路，引导受损细胞走向“自我毁灭”。然而，当咖啡因抑制了ATM的活性，p53的作用就无法正常发挥，细胞凋亡被抑制，异常细胞可能得以逃脱清除机制并进一步演化为肿瘤细胞。据研究作者称，这是迄今为止对芬兰人群开展的最大规模MR研究之一。总的来说，这项研究提供了长期较高血浆咖啡因水平与肺癌风险增加之间的因果关联的证据，且这种遗传证据不太受水平多效性的影响。咖啡喝多了真的安全吗？值得注意的是，上述研究聚焦的并不是“咖啡”本身，而是其最核心的功能性成分——咖啡因。这是因为咖啡因不仅是咖啡中含量最丰富的活性物质，更是影响神经系统、代谢功能、心血管健康等多个方面的关键因子。此前我们也提到，咖啡因的代谢主要依赖肝脏中的CYP1A2酶系。然而，CYP1A2的活性在个体之间存在显著差异，有些人代谢咖啡因很快，有些人则代谢缓慢。这种酶活性的差异意味着：即使摄入相同量的咖啡，不同个体的血浆咖啡因浓度也可能相差甚远，从而带来不同的健康影响风险。说到这，很多人可能会产生一个实际而困扰的问题——既然血浆咖啡因浓度难以日常检测，那到底每天喝几杯咖啡算“危险”？对此，一项发表于Nature子刊 Scientific Reports的研究[2]提供了一个参考视角。这项研究尝试将“咖啡摄入量”与“癌症风险”进行量化分析，结果发现：咖啡摄入量与肺癌风险之间存在显著正相关。与不喝咖啡的人群相比，常规饮用咖啡者罹患肺癌的风险上升了28％。这意味着，即使是日常“多喝一杯”的小习惯，也可能悄悄推高健康风险。至于为何咖啡可能与肺癌有关，研究者提出了一种可能的解释：咖啡中某些生物活性成分，可能在不知不觉中影响着我们的患癌风险。其中一个被重点提到的“嫌疑分子”是丙烯酰胺——这是一种具有遗传毒性的化合物，曾在动物实验中被证实可引起DNA损伤，诱发氧化应激反应，进而促进癌细胞的形成。而咖啡，尤其是经过烘焙处理的咖啡饮品，正是我们日常饮食中丙烯酰胺的重要来源之一。咖啡豆在高温烘焙过程中，其内部的糖类与氨基酸发生美拉德反应，正是这一反应导致了丙烯酰胺含量的显著上升。看到这儿，相信不少咖啡党已经陷入纠结：难道以后真的要“戒咖啡”了吗？毕竟，关于咖啡的种种健康益处，早已有大量研究从不同角度给予支持。确实如此。例如，南方医科大学毛琛教授团队曾在Annals of Internal Medicine发表一项大型前瞻性队列研究[3]，结果显示：无论是无糖咖啡还是加糖咖啡，每天喝1.5-3.5杯（约250ml/杯），都能显著降低全因死亡风险，幅度高达28％-31％。换句话说，适量饮咖啡或许真的有益健康。但别急着高兴太早——这项研究同时指出，如果每天喝咖啡超过4.5杯，全因死亡风险不降反升，甚至增加了5％。这提示我们，咖啡虽可能带来一定的健康益处，但千万别贪杯。更为系统的证据来自发表于Ageing Research Reviews的一项综述性研究[4]。研究团队回顾了过去20年间、覆盖不同国家和种族的50余项流行病学研究，综合分析得出：每天适量饮用咖啡（2-3杯），与全因死亡率降低17％以及健康寿命延长约1.8年之间存在关联。不过，前方再次友情提醒，过量饮用咖啡不仅可能抵消健康红利，还可能带来焦虑、失眠、心悸等神经系统影响，甚至引发胃肠道不适。看来，咖啡带来的健康影响确实是“几家欢喜几家愁”。一方面，它富含多种有益植物化学物，适量饮用甚至可能带来延长寿命、降低全因死亡率的好处；另一方面，关于其潜在促癌作用的研究也在不断涌现，让不少人陷入纠结。不过，面对这些针对负面作用的研究，并不意味着我们要对“咖啡”全盘否定。因为，咖啡是一种复杂的混合饮品，里面既包含可能带来健康隐患的成分（如咖啡因、丙烯酰胺等），也富含如多酚、类黄酮等对身体有益的植物活性物质。因此，真正需要我们注意的，并不是要“一刀切”地戒掉咖啡，而是更理性地看待它。尤其是对咖啡的忠实爱好者来说，在享受那杯提神饮品的同时，也别忘了适量才是健康的关键。仍需指出的是，研究[1]仅包括芬兰人群，咖啡因对不同地理人群癌症风险的遗传效应尚不清楚。此外，研究中使用的汇总水平数据限制了对咖啡因与癌症剂量-反应关系的探究。研究[2]尚不能推断因果关系。参考资料：[1]Wang, H., Ma, K., Shan, M.et al. Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization. Eur J Nutr 64, 145 (2025). https://doi.org/10.1007/s00394-025-03663-4[2]Jabbari, M., Salari-Moghaddam, A., Bagheri, A. et al. A systematic review and dose–response meta-analysis of prospective cohort studies on coffee consumption and risk of lung cancer. Sci Rep 14, 14991 (2024). https://doi.org/10.1038/s41598-024-62619-6[3]Liu D, Li ZH, Shen D, Zhang PD, Song WQ, Zhang WT, Huang QM, Chen PL, Zhang XR, Mao C. Association of Sugar-Sweetened, Artificially Sweetened, and Unsweetened Coffee Consumption With All-Cause and Cause-Specific Mortality : A Large Prospective Cohort Study. Ann Intern Med. 2022 May 31. doi: 10.7326/M21-2977. Epub ahead of print. PMID: 35635846.[4] Lopes CR, Cunha RA. Impact of coffee intake on human aging: Epidemiology and cellular mechanisms. Ageing Res Rev. 2024 Dec;102:102581. doi: 10.1016/j.arr.2024.102581. Epub 2024 Nov 16. PMID: 39557300.撰文 | 木白编辑 | 木白● 热议！饶毅：请勿错怪王辰教授，4+4没有问题！公众并非质疑制度创新本身，关键这是否为少数人留下了“钻空子”和“权力寻租”的机会？● 教训！广东大三甲出现低级错误！患者手术成功，全麻苏醒过程中缺氧30分钟，导致脑死亡！麻醉无小事，近期出现两起生殖微创术后死亡事件● 延寿7-8年，护肝，减重又抗癌！三登顶刊：饮料中这种常见成分还能减轻肝损伤，延缓衰老版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

信使RNA临床结果临床研究

2025-04-25

·Cytiva学堂

Biacore解码：突破慢性病治疗的天然分子密钥

在慢性病治疗这场持久战中，人类从未停止寻找破局密钥。古老医典里沉睡的草本精华，如今正通过Biacore分子互作分析技术焕发新生。通过Biacore技术的最新研究，科学家成功解析了三大天然成分的分子作用机理。Plumbagin通过靶向lncRNA改善肌肉萎缩；异甘草苷特异性结合TRDMT1缓解心脏毒性；咖啡因调控Dusp9改善脂肪肝炎；这些发现不仅为难治性疾病带来新希望，更展现了现代生物技术在天然产物研究中的应用价值。让我们一起见证这场传统与现代交融的科研突破...Plumbagin抗肌肉萎缩机制肌肉萎缩作为多种慢性疾病的共同病理特征，目前临床治疗面临重大挑战。广州中医药大学团队在《Phytomedicine》发表突破性研究，不仅证实骨骼肌卫星细胞分化障碍和NF-κB通路过度激活是肌肉萎缩的关键驱动因素，并且首次阐明中药活性成分Plumbagin通过靶向lncRNA DANCR改善肌肉萎缩的分子机制。研究发现，中药成分Plumbagin通过靶向降解长链非编码RNA DANCR，阻断NF-κB通路激活，从而有效改善肌肉萎缩。团队利用Biacore技术验证了PB与DANCR的直接结合，SPR分析显示Plumbagin以KD值2.901×10⁻⁵ M的亲和力特异性结合DANCR，为Plumbagin调控NF-κB信号通路提供了直接证据。图1：Biacore检测Plumbagin与DANCR的结合传感图Biacore技术验证了Plumbagin通过靶向DANCR降解阻断NF-κB信号通路的激活，从而减轻肌肉萎缩。这一发现不仅为肌肉萎缩提供了新的治疗策略，还创新性地发现了首个靶向lncRNA的天然小分子，建立了RNA靶向药物筛选的新方法，为中药现代化研究提供了技术范式。异甘草苷改善阿霉素诱导的心肌毒性阿霉素是常用的抗癌药，常用于化疗，但阿霉素的心脏毒性（30%发生率）和右雷佐生的致癌风险，是当前肿瘤治疗中的重要临床挑战。异甘草苷（ISL）是从甘草中提取的黄酮类化合物，具有抗氧化、抗炎和抗肿瘤活性。山东中医药大学团队在《Phytomedicine》发表最新研究，通过Biacore技术证实异甘草苷（ISL）与TRDMT1的特异性结合，为缓解阿霉素（DOX）心脏毒性提供新靶点。在这项研究中，Biacore 1K被用于验证异甘草苷与m5C甲基转移酶TRDMT1之间的结合特性。研究人员首先通过分子对接实验预测了异甘草苷与TRDMT1的结合位点，并利用Biacore SPR技术进一步实验验证了两者的结合动力学特性。结果显示，异甘草苷与TRDMT1的结合具有“快上快下”的特性，平衡解离常数（KD）为4.9×10-7 M。这一结果不仅验证了分子对接的预测，还为异甘草苷通过调控TRDMT1改善心肌线粒体自噬提供了直接的实验依据。图2：Biacore检测异甘草苷与TRDMT1的结合传感图Biacore技术实时监测获得的"快上快下"结合动力学特征，准确反映了异甘草苷与靶蛋白的瞬时作用模式，为后续发现的TRDMT1-m5C-线粒体自噬调控通路奠定了分子基础，使传统中药活性成分的作用机制研究达到现代药理学标准。咖啡因改善代谢相关脂肪性肝炎机制代谢相关脂肪性肝病（MASLD）全球患病率达25%，其进展型代谢相关脂肪性肝炎（MASH）可导致肝纤维化甚至肝癌。目前临床缺乏特效药物，而流行病学显示咖啡因摄入与肝病风险降低显著相关，但具体机制不明。上海中医药大学附属曙光医院团队近期在《Redox Biology》发表重要成果，利用Biacore技术解析咖啡因（CAFF）改善代谢相关脂肪性肝炎（MASH）的分子机制，为药物靶点发现提供范例。研究团队通过分子对接预测咖啡因与双特异性磷酸酶9（Dusp9）结合后，采用Biacore T200进行实验验证。研究人员将Dusp9蛋白固定在CM7芯片上，进样不同浓度的咖啡因溶液，实时检测结合和解离过程。结果显示，咖啡因与Dusp9的结合具有剂量依赖性，亲和力为1.86×10⁻⁴ M。这一结果不仅验证了分子对接的预测，还为咖啡因通过调控Dusp9改善MASH提供了直接的实验依据。图3：Biacore检测咖啡因与Dusp9的结合传感图Biacore技术的应用，使研究人员能够突破传统研究方法的局限，首次从分子互作角度解析咖啡因改善脂肪肝的作用机制。这种高精度、实时动态的检测手段，为天然产物活性成分的靶点发现和机制研究提供了可靠的技术支撑，展现出在代谢性疾病研究领域的重要价值。结语从肌肉萎缩到心脏毒性，再到脂肪肝炎，Biacore技术为天然活性成分研究提供了重要技术支撑：实现了分子互作的实时动态检测；提供了精确的结合动力学参数；建立了从靶点发现到机制验证的研究体系；我们看见的不仅是天然产物的重生，更是一个用技术解码生命、用传统启迪未来的医疗新纪元。随着更多机制被揭示，我们期待这些源自天然产物，能通过现代科技的“翻译”，为全球患者带来更安全有效的治疗方案。参考文献：1. Liu, Yu et al. “Plumbagin alleviates muscle atrophy in female mice through inhibiting the DANCR/NF-κB axis.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 136 (2025): 156282. doi:10.1016/j.phymed.2024.156282.2.Fu, Jiaqi et al. “Isoliquiritin targeting m5C RNA methylation improves mitophagy in doxorubicin-induced myocardial cardiotoxicity.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 136 (2025): 156293. doi:10.1016/j.phymed.2024.156293.3.Xin, Xin et al. “Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9.” Redox biology vol. 80 (2025): 103499. doi:10.1016/j.redox.2025.103499.

临床结果临床2期

2025-01-23

·PRNewswire

FUTURE OF HEALTH: CARDONE VENTURES PARTNERS WITH REVIV TO LAUNCH THE WORLD'S FIRST PRECISION NUTRITION SYSTEM IN THE UK

LONDON, Jan. 23, 2025 /PRNewswire/ -- Cardone Ventures, the business growth and investment firm led by Brandon Dawson and Grant Cardone, is proud to announce the UK launch of the world's first patented 10X Precision Nutrition System in partnership with REVIV Global, the leader in personalized health and IV therapy. This milestone event marks the first expansion of Cardone Ventures' portfolio company, 10X Health, outside the United States, setting a new global standard for personalized health solutions. With REVIV's expertise in IV therapy, boasting over 3 million therapies delivered worldwide, and 10X Health's cutting-edge genetic technology, this collaboration introduces a revolutionary way for individuals to optimize their health and well-being through their unique genetic makeup. The UK launch serves as the first step in a strategic international rollout, with plans to expand to other key markets globally. Revolutionizing Health with Unmatched Genetic Insights The 10X Precision Genetic Test combines cutting-edge technology with artificial intelligence to analyze up to 20 million genetic variations, delivering unparalleled insights into an individual's biological data with 99.97% accuracy. Developed in Austria by renowned biotechnologist Dr. Daniel Wallerstorfer, PhD, the system represents the pinnacle of precision health science. The process is simple and non-invasive: customers provide an oral swab sample, which is analyzed at a state-of-the-art laboratory using Micro Array technology to capture 700,000 DNA variations. AI-powered bioinformatics then expands the analysis to 20 million variations, delivering a detailed, actionable report within just six weeks. The comprehensive 400+ page report provides insights into nutrition, weight management, and lifestyle factors, such as: Caffeine consumption and absorption Inflammation and immune system performance Salt sensitivity and blood pressure Fat distribution and muscle preservation And much more. More information can be found on: Transforming Health and Wellness Solutions With results in hand, customers gain access to personalized health tools, including: 10X Precision Supplements: Custom-formulated, patented micro-bead supplements designed for optimal absorption and bioavailability to improve digestion, immunity, skin health, energy levels, and metabolic function. 10X Precision IV Drip Therapy: The only IV therapy designed using an individual's unique genetic profile, delivering the ultimate in tailored wellness. Clients can book their bespoke IV therapy via a QR code on their report, accessible at any REVIV or 10X Health clinic worldwide. "This partnership eradicates the guesswork of health fads and trends, replacing them with science-backed, data-driven solutions that uniquely cater to each individual," said Sarah Lomas, CEO of REVIV Global. "With more than a decade of R&D, 3 million IVs delivered, and the integration of cutting-edge genetic science, we're empowering people to take control of their health in a way that's never been possible before. This is the future of health and wellness." A Global Vision with Local Impact "This launch represents a monumental step in achieving our mission to revolutionize the health and wellness industry," said Brandon Dawson, CEO of Cardone Ventures and 10X Health. "By combining 10X's precision genetic technology with REVIV's proven expertise in personalized and precision health solutions, we're delivering an unparalleled system that empowers individuals to optimize their health with unmatched accuracy and accessibility." The UK launch is just the beginning of an ambitious global strategy to bring personalized, precision health solutions to markets around the world. About Cardone Ventures Cardone Ventures, co-founded by scaling experts Brandon Dawson (CEO), Natalie Dawson (President), as well as their partner, renowned entrepreneur and equity fund manager Grant Cardone, is a business consultancy and investment management firm that specializes in helping small and medium-sized businesses scale to achieve exponential growth. With a mission to empower business owners with the tools and strategies necessary to increase their sales, optimize their operations, and enhance their team's performance, Cardone Ventures has become a pivotal force in the realm of business development. Cardone Ventures offers a suite of business services, including business education workshops, consulting services, and business formatting, along with debt and equity investments. The firm's innovative approach is designed to align with the unique vision and goals of each client, ensuring personalized solutions that drive real results. One of Cardone Ventures' notable early-stage investments is 10X Health, a portfolio company that has emerged as a global leader in precision health solutions. Through strategic guidance and support, Cardone Ventures has helped 10X Health innovate and expand, setting a new standard in the health and wellness industry. Cardone Ventures' commitment to excellence and proven methodologies have earned it a prestigious reputation in the industry, helping clients not only meet but exceed their ambitious business objectives. As the company continues to expand its reach, it remains dedicated to fostering entrepreneurial success across various sectors, shaping the future of businesses worldwide. For more information about Cardone Ventures and how its cutting-edge services can transform your business, visit: About REVIV Global Ltd REVIV is a global wellness provider renowned for its pioneering efforts in IV therapy and vitamin injections. Established with the vision to restore vitality and enhance well-being, REVIV has become a leader in preventative healthcare services that are tailored to the demands of modern life. The company's signature IV therapies and booster shots are designed to maximize wellness, hydration, and energy, catering to individuals seeking to rejuvenate their health and boost their immune system. Contact: [email protected] SOURCE Cardone Ventures WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与枸橼酸咖啡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07603	枸橼酸咖啡因	N06BC01	DB00201

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新生儿呼吸暂停	加拿大	CHIESI Farmaceutici SpA	2020-03-04
呼吸暂停	美国	Hikma Pharmaceuticals USA, Inc.	1999-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04950660 (CTgov)	临床4期	雄激素不敏感综合征 \| 疼痛 \| 特发性脊柱侧弯	61	Caffeine Tablet (Caffeine Arm)	窪鏇積鏇窪鹽膚齋膚鹹(蓋簾壓願網壓選餘範夢) = 積獵觸觸襯襯壓艱鹽艱衊獵製範夢廠積觸艱簾 (夢網夢鹹憲製積觸鏇願, 0.41) 更多	-	2025-02-21
				Placebo+Caffeine Tablet (Placebo Arm)	窪鏇積鏇窪鹽膚齋膚鹹(蓋簾壓願網壓選餘範夢) = 膚醖顧觸憲鏇範願壓夢衊獵製範夢廠積觸艱簾 (夢網夢鹹憲製積觸鏇願, 0.33) 更多
NCT03913221 (CTgov)	临床1期	缺氧缺血性脑病	17	Caffeine Citrate 5 mg/kg (Low Dose Caffeine (5 mg/kg))	構簾遞艱蓋齋艱範醖鹽(蓋淵憲遞願襯鬱顧簾築) = 餘艱齋齋鬱憲鬱鏇淵衊壓鹽繭構襯餘夢艱衊醖 (壓餘選餘鏇願鹹壓醖壓, 324.96) 更多	-	2024-09-19
				Caffeine Citrate 10 mg/kg (High Dose Caffeine (10 mg/kg))	構簾遞艱蓋齋艱範醖鹽(蓋淵憲遞願襯鬱顧簾築) = 網廠膚繭壓艱衊艱鹽鏇壓鹽繭構襯餘夢艱衊醖 (壓餘選餘鏇願鹹壓醖壓, 134.42) 更多
NCT03340727 (MoCHA, CTgov)	临床3期	呼吸暂停	827	Placebo	構製蓋築鬱鹽衊齋構鏇(窪網構遞鏇築構窪構壓) = 齋膚鏇窪構膚選衊淵願窪窪築憲淵衊蓋鏇繭築 (鑰窪鑰醖願選鏇齋獵淵, 糧蓋窪餘鹽願齋齋範廠 ~ 網鬱鏇鑰築膚鏇憲願築) 更多	-	2024-06-28
NCT02323698 (CTgov)	临床1/2期	脊髓损伤 \| 缺氧	36	AIH+Caffeine (Caffeine/AIH)	顧鏇遞繭糧繭願壓範構(淵鏇鏇獵鹽廠鹽窪廠窪) = 衊艱選網鹽襯廠網選衊艱範遞夢淵顧憲憲觸繭 (遞繭衊選糧網餘蓋廠壓, 2.2) 更多	-	2022-08-09
				Placebo (Placebo/AIH)	顧鏇遞繭糧繭願壓範構(淵鏇鏇獵鹽廠鹽窪廠窪) = 餘構壓顧顧鹽窪遞鹹夢艱範遞夢淵顧憲憲觸繭 (遞繭衊選糧網餘蓋廠壓, 2.2) 更多
NCT03577730 (CTgov)	早期临床1期	术后疼痛	71	Caffeine Citrate (Experimental)	積窪憲淵鹹衊觸鹹網蓋(築餘製齋醖醖壓壓製憲) = 夢觸網觸襯蓋積鹹選鏇衊衊壓網選齋餘觸艱憲 (鏇廠夢鹹網選構簾鹽選, 願選夢範鹹壓範遞繭齋 ~ 範襯艱齋衊網築齋繭選) 更多	-	2021-10-06
				Dextrose Water (Control)	積窪憲淵鹹衊觸鹹網蓋(築餘製齋醖醖壓壓製憲) = 鑰糧願窪餘糧網顧鑰範衊衊壓網選齋餘觸艱憲 (鏇廠夢鹹網選構簾鹽選, 構窪夢顧壓廠網鑰觸觸 ~ 構廠鹽蓋糧艱鏇選觸願) 更多
NCT02974114 (CTgov)	临床4期	疼痛 \| 急性疼痛 \| 头痛	21	Paracetamol+caffeine (Paracetamol and Caffeine)	遞遞淵鬱顧鹽顧選範壓(觸構範遞鹽遞願廠繭蓋) = 襯獵廠襯膚簾衊夢糧鑰鹹構製繭願範製蓋網鬱 (網構積鏇顧廠蓋鏇憲鏇, 積憲鏇鏇遞鬱壓顧獵廠 ~ 夢簾築鏇顧選鹹淵選鹽) 更多	-	2018-08-28
				Paracetamol (Paracetamol)	遞遞淵鬱顧鹽顧選範壓(觸構範遞鹽遞願廠繭蓋) = 簾憲積鬱艱鹹淵壓鹹醖鹹構製繭願範製蓋網鬱 (網構積鏇顧廠蓋鏇憲鏇, 鹽窪簾繭製鏇願選壓蓋 ~ 繭鹹糧壓憲蓋獵衊簾廠) 更多
NCT02567968 (CTgov)	临床4期	麻醉	8	Placebo Control (Placebo)	壓鬱範鬱膚鏇築餘衊顧(醖鑰繭壓醖製願鏇範願) = 築製觸餘築淵糧鬱憲襯觸製壓蓋齋鬱願鬱網製 (醖顧鑰衊獵鹽糧鬱鹽積, 3.9) 更多	-	2018-07-18
				Caffeine (Caffeine)	壓鬱範鬱膚鏇築餘衊顧(醖鑰繭壓醖製願鏇範願) = 窪獵簾艱壓艱憲遞積壓觸製壓蓋齋鬱願鬱網製 (醖顧鑰衊獵鹽糧鬱鹽積, 5.1) 更多
NCT02461693 (CTgov)	N/A	认知	205	Caffeine (Caffeine)	襯製齋鏇鏇淵築遞壓齋(鏇選糧觸範鹽醖願餘窪) = 範範鏇廠窪憲製網餘獵簾糧繭繭鬱願簾蓋夢醖 (衊齋鹹夢憲餘餘製膚獵, 1.98) 更多	-	2017-07-12
				Placebo (Placebo)	襯製齋鏇鏇淵築遞壓齋(鏇選糧觸範鹽醖願餘窪) = 壓網製襯衊獵醖蓋窪壓簾糧繭繭鬱願簾蓋夢醖 (衊齋鹹夢憲餘餘製膚獵, 2.86) 更多
NCT01751724 (CTgov)	N/A	呼吸衰竭 \| 呼吸暂停 \| 早产	87	Caffeine citrate (Caffeine Arm)	構繭淵襯構廠顧觸憲齋(構醖夢膚糧製簾淵顧繭) = 築製鏇窪襯觸餘壓網築鏇醖醖選築餘艱顧選齋 (廠遞簾獵繭願獵鏇蓋衊, 選鹽顧獵鹹鑰簾醖齋醖 ~ 膚壓齋範醖鏇糧鹽憲積) 更多	-	2017-06-19
				normal saline (Placebo Arm)	構繭淵襯構廠顧觸憲齋(構醖夢膚糧製簾淵顧繭) = 鬱願鬱獵憲壓簾製衊壓鏇醖醖選築餘艱顧選齋 (廠遞簾獵繭願獵鏇蓋衊, 獵製餘構鏇廠糧積醖製 ~ 膚艱蓋範遞積廠鹹願鏇) 更多
NCT00182312 (CAP, Pubmed \| JAMA Pediatr)	临床3期	呼吸暂停	1,202	Caffeine citrate	糧淵夢簾簾艱構製蓋獵(淵鬱構蓋艱齋觸夢鏇顧): adjusted odds ratio = 1.32 (95% CI, 0.85 ~ 2.07) 更多	-	2017-06-01
				Placebo